Published in Medical Imaging Law Weekly, September 5th, 2006
Study 1: Breast cancer clinicopathologic response to primary chemotherapy could be predicted by reductions in magnetic resonance (MR) imaging-determined size of the primary tumor.
In a recent report published in the journal Radiology, researchers in England conducted a study "to prospectively document changes in contrast agent kinetics in patients with primary breast cancer treated with systemic chemotherapy after 1 or 2 cycles and to determine whether kinetic measures can be used to predict final clinicopathologic response. Institutional committees...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Imaging Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.